Elite Dividend Stocks To Own In September 2026

Bond yields are back at two decade highs and cash finally pays a visible rate, yet many savers still watch inflation quietly erode their spending power. Reliable dividend payers offering more than a 3% yield with room to keep those cheques coming can help bridge that gap. This piece highlights three high quality income stocks from our screen that aims to focus on well covered, growing and steady payouts.

The three stocks covered below are just a starting point, since the full Dividend Powerhouses screen surfaced 2,274 more companies with 3%+ yields and equally compelling income stories that are not covered here. To identify and analyze potential high conviction ideas that fit your own income goals, head straight to the Dividend Powerhouses (3%+ Yield) screener.

NIKE (NKE)

Overview: Nike is a global sportswear business that designs, makes and sells athletic footwear, apparel, accessories and related services worldwide while returning cash to shareholders through regular dividends.

Operations: Nike generates most of its revenue from the NIKE Brand across North America at about US$20.5b and Europe, Middle East & Africa at about US$12.6b, with total sales of roughly US$46.4b split between the United States at about US$20.4b and markets outside the US at about US$26b.

Market Cap: US$53.5b

Nike matters for this dividend screen because it couples a global sportswear franchise with a regular cash payout. This currently offers income investors a relatively high yield backed by a long record of quarterly cheques.

"However, there are some risks for the company, represented by the High uncertainty rating, showing that Nike, despite having a history of success, needs to keep reinventing itself providing, as always, great products to its clients."

Investor outcomes from here hinge on how one unresolved pressure on Nike’s cash generation and profitability trajectory ultimately plays out.

That pressure point is exactly what the full narrative for NIKE unpacks, highlighting where Nike’s cash engine could accelerate again and where reinvention risks might still be masking resilience.

Accenture (ACN)

Overview: Accenture is a global consulting and outsourcing business that helps large organisations modernise operations, move to the cloud and apply AI, generating cash flows that support its dividend profile.

Operations: Accenture earns about US$22.3b from Products clients, US$14.9b from Health & Public Service, US$13.8b from Financial Services, US$12.4b from Communications, Media & Technology and US$9.8b from Resources, with Asia Pacific contributing roughly US$10.6b.

Market Cap: US$112.3b

Dividend investors looking at Accenture are weighing up whether a global consulting and managed services business can keep turning long contracts, cloud work and AI-focused projects into the kind of cash stream that supports its payout profile.

"The market is asking whether Accenture can convert AI from a threat into a growth engine."

Investor outcomes from here depend on how one less visible pressure on Accenture’s earnings mix and margin profile ultimately resolves.

That turning point is exactly what the full narrative for Accenture lays out, separating stalled demand from accelerating AI work and highlighting where Accenture’s cash engine could quietly be strengthening.

Novo Nordisk (CPSE:NOVO B)

Overview: Novo Nordisk develops and sells diabetes, obesity and rare disease medicines, with cash-generative GLP-1 treatments helping support consistent dividend payouts.

Operations: Novo Nordisk generates about DKK 309b from Diabetes and Obesity Care and roughly DKK 20b from Rare Disease products.

Market Cap: DKK1,116.7b

Novo Nordisk is included in this dividend screen because its GLP-1 diabetes and obesity therapies generate cash flows that currently support a yield above 3%, and its pipeline is intended to help keep those payments supported over time.

"The company is allocating capital to R&D for next-generation obesity drugs, including oral versions and drugs with longer-lasting effects. It is also acquiring companies and technologies with the goal of expanding its pipeline beyond diabetes and obesity, such as into cardiovascular disease and chronic kidney disease."

Investor outcomes from here depend in part on how one unresolved pressure on Novo Nordisk’s future cash conversion into reliable dividend coverage ultimately develops.

That pressure is exactly what the full narrative for Novo Nordisk unpacks, showing how Novo Nordisk’s pipeline, capital allocation and GLP-1 cash flows could be accelerating or masking future income risk.

Seeking Alternatives Before The Crowd?

Fresh ideas move first. The strongest themes often break out quietly, then momentum builds and prices start flying. Catch the under the radar stories while it matters and get in early.

• Capture early signals in high potential miners before sentiment turns by scanning the curated 36 elite gold producer stocks focused on producers with meaningful scale and liquidity.
• Ride structural demand for electrification and grid upgrades by reviewing the hand picked 39 power grid technology and infrastructure stocks targeting businesses tied directly to transmission, hardware and supporting tech.
• Target fast moving automation leaders by running through the focused 93 robotics and automation stocks packed with companies building robots, components and software for real world adoption.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com